Pulmonary hypertension adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: high pressure in the lung arteries

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 20,554 adverse event reports that record the MedDRA preferred term Pulmonary hypertension. In plain words, the term means: high pressure in the lung arteries. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 867 reports in the 12 months to June 2026 and 973 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

High pressure in the lung arteries. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 110 drug pages with 50 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Pulmonary hypertension name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		52
Acetylsalicylic Acid		52
Adcirca	Phosphodiesterase 5 inhibitor	293
Adempas	Soluble guanylate cyclase stimulator	413
Alendronate sodium	Bisphosphonate	63
Ambrisentan	Endothelin receptor antagonist	1,332
Amiodarone		79
Amiodarone hydrochloride	Antiarrhythmic	82
Amlodipine	Calcium channel blocker	71
Aredia		76
Aspirin	Nonsteroidal anti-inflammatory drug	165
Avandia		286
Avastin	Vascular endothelial growth factor inhibitor	66
Avonex	Interferon beta	72
Bevacizumab	Vascular endothelial growth factor inhibitor	84
Bisoprolol	beta-Adrenergic blocker	103
Bisoprolol fumarate	beta-Adrenergic blocker	55
Bosentan	Endothelin receptor antagonist	131
Busulfan	Alkylating drug	94
Carboplatin	Platinum-based drug	82
Carfilzomib	Proteasome inhibitor	94
Carvedilol	alpha-Adrenergic blocker	58
Cholecalciferol		70
Cisplatin	Platinum-based drug	54
Clopidogrel	P2Y12 platelet inhibitor	80
Cyclophosphamide	Alkylating drug	298
Cyclosporine	Calcineurin inhibitor immunosuppressant	84
Cytarabine	Nucleoside metabolic inhibitor	61
Dasatinib	Kinase inhibitor	176
Dexamethasone	Corticosteroid	127
Diclofenac	Nonsteroidal anti-inflammatory drug	59
Digoxin	Cardiac glycoside	286
Doxorubicin	Anthracycline topoisomerase inhibitor	65
Eliquis	Factor Xa inhibitor	100
Enbrel	Tumor necrosis factor blocker	136
Entresto	Angiotensin 2 receptor blocker	139
Epoprostenol sodium		61
Esbriet	Pyridone	107
Esomeprazole	Proton pump inhibitor	52
Etoposide	Topoisomerase inhibitor	106
Exjade	Iron chelator	56
Fentanyl	Opioid agonist	52
Flolan		171
Fluorouracil	Nucleoside metabolic inhibitor	51
Fosamax	Bisphosphonate	153
Furosemide	Loop diuretic	199
Herceptin	HER2/neu receptor antagonist	70
Humira		331
Ibuprofen	Nonsteroidal anti-inflammatory drug	81
Imatinib	Kinase inhibitor	87
Jakafi	Janus kinase inhibitor	65
Kyprolis	Proteasome inhibitor	66
Lasix	Loop diuretic	85
Letairis	Endothelin receptor antagonist	631
Macitentan	Endothelin receptor antagonist	130
Melphalan	Alkylating drug	72
Metformin	Biguanide	75
Methotrexate	Folate analog metabolic inhibitor	198
Metoprolol	beta-Adrenergic blocker	62
Mycophenolate mofetil	Antimetabolite immunosuppressant	127
Nilotinib	Kinase inhibitor	65
Nitric oxide	Vasodilator	60
Nivolumab	Programmed death Receptor-1 blocking antibody	58
NuvaRing	Estrogen	102
Ofev	Kinase inhibitor	222
Omeprazole	Proton pump inhibitor	86
Opsumit	Endothelin receptor antagonist	1,402
Orenitram	Prostacycline vasodilator	246
Oxbryta		57
Pantoprazole	Proton pump inhibitor	90
Paxil	Serotonin reuptake inhibitor	87
Pradaxa	Direct thrombin inhibitor	56
Prednisolone	Corticosteroid	149
Prednisone	Corticosteroid	223
Prograf	Calcineurin inhibitor immunosuppressant	63
Ramipril	Angiotensin converting enzyme inhibitor	99
Rebif	Interferon beta	81
Remodulin	Prostacycline vasodilator	1,150
Revatio	Phosphodiesterase 5 inhibitor	635
Revlimid	Thalidomide analog	107
Rinvoq	Janus kinase inhibitor	51
Rituximab	CD20-directed cytolytic antibody	173
Selexipag	Prostacyclin receptor agonist	56
Sertraline	Serotonin reuptake inhibitor	59
Sildenafil	Phosphodiesterase 5 inhibitor	219
Sildenafil citrate	Phosphodiesterase 5 inhibitor	140
Simvastatin	HMG-CoA reductase inhibitor	67
Soliris	Complement inhibitor	56
Spironolactone	Aldosterone antagonist	97
Sprycel	Kinase inhibitor	133
Synagis	Respiratory syncytial virus Anti-F protein monoclonal antibody	51
Tacrolimus	Calcineurin inhibitor immunosuppressant	136
Tadalafil	Phosphodiesterase 5 inhibitor	176
Tiotropium bromide	Anticholinergic	69
Torsemide	Loop diuretic	75
Tracleer	Endothelin receptor antagonist	993
Treprostinil	Prostacycline vasodilator	220
Tyvaso	Prostacycline vasodilator	596
Tyvaso DPI	Prostacycline vasodilator	119
Uptravi	Prostacyclin receptor agonist	656
Valsartan	Angiotensin 2 receptor blocker	78
Velcade	Proteasome inhibitor	78
Veletri	Prostacycline vasodilator	403
Ventavis		354
Vincristine		64
Vioxx		190
Xarelto	Factor Xa inhibitor	129
Xeljanz	Janus kinase inhibitor	57
Yasmin		54
Zometa		111

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 46 pharmacologic classes with 100 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Pulmonary hypertension name, in order of name
Class	Reports with this term
Aldosterone antagonist	129
Alkylating drug	528
alpha-Adrenergic blocker	114
Angiotensin 2 receptor blocker	356
Angiotensin converting enzyme inhibitor	184
Anthracycline topoisomerase inhibitor	127
Antiarrhythmic	121
Anticholinergic	100
Antimetabolite immunosuppressant	195
Atypical antipsychotic	198
Benzodiazepine	100
beta-Adrenergic blocker	358
Biguanide	111
Bisphosphonate	231
Calcineurin inhibitor immunosuppressant	295
Cardiac glycoside	290
CD20-directed cytolytic antibody	217
Corticosteroid	658
Endothelin receptor antagonist	4,619
Estrogen	119
Factor Xa inhibitor	362
Folate analog metabolic inhibitor	243
HER2/neu receptor antagonist	149
HMG-CoA reductase inhibitor	200
Interferon beta	155
Janus kinase inhibitor	222
Kinase inhibitor	1,130
Loop diuretic	370
Nonsteroidal anti-inflammatory drug	413
Nucleoside metabolic inhibitor	255
Opioid agonist	231
P2Y12 platelet inhibitor	143
Phosphodiesterase 5 inhibitor	1,499
Platinum-based drug	166
Programmed death Receptor-1 blocking antibody	113
Prostacyclin receptor agonist	712
Prostacycline vasodilator	2,776
Proteasome inhibitor	288
Proton pump inhibitor	379
Pyridone	122
Serotonin reuptake inhibitor	322
Soluble guanylate cyclase stimulator	436
Thalidomide analog	227
Topoisomerase inhibitor	130
Tumor necrosis factor blocker	272
Vascular endothelial growth factor inhibitor	161

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Pulmonary hypertension, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Pulmonary hypertension
Age	Reports	Share
Under 2	592	2.9%
2 to 11	434	2.1%
12 to 17	203	1%
18 to 44	2,132	10.4%
45 to 64	4,633	22.5%
65 to 74	3,411	16.6%
75 and over	2,931	14.3%
Age not given	6,218	30.3%

Sex of the patient in the reports that record Pulmonary hypertension
Sex	Reports	Share
Female	12,350	60.1%
Male	6,533	31.8%
Unknown or not given	1,671	8.1%

Age and sex are as the report gives them. 62.9% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Pulmonary hypertension: adverse event reports that record this term. https://reportedreactions.com/reaction/pulmonary-hypertension/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Pulmonary hypertension mean in an adverse event report?

In plain words: high pressure in the lung arteries. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page